Gold and Silver Nanoparticles 2023
DOI: 10.1016/b978-0-323-99454-5.00006-8
|View full text |Cite
|
Sign up to set email alerts
|

Silver and gold nanoparticles: Potential cancer theranostic applications, recent development, challenges, and future perspectives

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 168 publications
0
8
0
1
Order By: Relevance
“…Recently, nanotechnology is emerging as a promising technology in several biomedical sectors for the treatment of various diseases such as cardiovascular diseases, wound healing, neurodegenerative diseases, microbial infections including cancer [72,73]. Among various nanomaterials, transition metal nanoformulations have been extensively used for cancer therapy because of their unique physiochemical properties [72,[74][75][76][77][78][79][80] These metal-based nanoformulations are advantageous over the conventionally treated anti-cancer drugs because of their site specific targeting, controlled release and less side effects. To this, scientists are focusing on the design, development and fabrication of economic, biocompatible, stable, ecofriendly nitroprusside-based metal nanocomplexes for the delivery of NO, metal ions or drugs in to the tumor microenvironment [10][11][12][13].…”
Section: Nitroprusside Based Nanomaterialsmentioning
confidence: 99%
See 1 more Smart Citation
“…Recently, nanotechnology is emerging as a promising technology in several biomedical sectors for the treatment of various diseases such as cardiovascular diseases, wound healing, neurodegenerative diseases, microbial infections including cancer [72,73]. Among various nanomaterials, transition metal nanoformulations have been extensively used for cancer therapy because of their unique physiochemical properties [72,[74][75][76][77][78][79][80] These metal-based nanoformulations are advantageous over the conventionally treated anti-cancer drugs because of their site specific targeting, controlled release and less side effects. To this, scientists are focusing on the design, development and fabrication of economic, biocompatible, stable, ecofriendly nitroprusside-based metal nanocomplexes for the delivery of NO, metal ions or drugs in to the tumor microenvironment [10][11][12][13].…”
Section: Nitroprusside Based Nanomaterialsmentioning
confidence: 99%
“…The majority of conventionally prepared silver nanoparticles exhibit several drawbacks such as photobleaching, stability, increased concentration of Ag + , non specific targeting etc. that limits their therapeutic efficacy [76]. To this, Londhe et al designed and synthesized silver nitroprusside nanoparticles (AgNNPs) by the interaction between silver nitrate and FDA approved SNP as well as explored the anticancer activity in breast carcinoma [10].…”
Section: Silver Nitroprussidementioning
confidence: 99%
“… 122 , 219 Furthermore, they can be used in a variety of scenarios, including cancer therapy, wound healing, biosensing, tissue engineering, and diagnostics. 220 , 221 …”
Section: Advantages Of Biomedical Applications Of Green Synthesized A...mentioning
confidence: 99%
“…[43][44][45] In addition, nanoparticles are employed in cancer theranostics, an approach where anticancer and imaging agents are combined in a single system. [46][47][48] In this review, conventional and emerging therapies for retinoblastoma were discussed, with an emphasis on the recent developments, challenges and prospects of the use of nanoparticles as novel delivery systems for chemotherapeutic drugs and imaging agents. The potential use of nanoparticles in active drug targeting and in the delivery of phytochemicals to the retinoblastoma cells was also discussed.…”
Section: Nanoscale Advances Reviewmentioning
confidence: 99%
“…43–45 In addition, nanoparticles are employed in cancer theranostics, an approach where anticancer and imaging agents are combined in a single system. 46–48…”
Section: Introductionmentioning
confidence: 99%